Melanoma: Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant
Melanoma That Cannot Be Removed by Surgery
Will receiving dabrafenib and trametinib with a break in treatment extend the time
before your cancer gets worse?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This study will allow the researchers to know whether a break in treatment is better,
the same, or worse than continuous treatment of dabrafenib and trametinib. To be better,
the break in treatment approach should extend the time before cancer gets worse by
about 4 to 6 months compared to the continuous treatment approach.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02196181?term=SWOG+1320&rank=2
Study Reference #: CMEL-14114
Lead Researcher (Principal Investigator)
Lead Researcher: Deepak Sahasrabudhe, MD
Study Contact InformationStudy Coordinator: Park Bogan
Phone: (585) 276-4415
Additional Study Details
Learn More About These Conditions
More information about Melanoma
Trial Not Found
The study you are looking for is not active at this time.
Return to Search